Plain-English Summary
FDA cleared the first OTC CGM and explicitly described intended users and limits. The source is crucial for preventing wellness-CGM claims from outrunning device labeling.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
78/100
Useful Public Evidence
- Evidence tier
- 92/100, weight 18%
- Design strength
- 92/100, weight 18%
- Applicability
- 86/100, weight 16%
- Endpoint relevance
- 58/100, weight 16%
- Limitations transparency
- 50/100, weight 12%
- Safety signal usefulness
- 69/100, weight 10%
- Publication/source strength
- 94/100, weight 10%
Useful for context, but limited by limitations transparency, endpoint relevance, safety signal usefulness.
How the study framework works ->Key Findings
- FDA cleared the first OTC CGM and explicitly described intended users and limits.
- The source is crucial for preventing wellness-CGM claims from outrunning device labeling.
Limitations
- Regulatory communication, not a behavioral outcome trial.
Why It Matters
This record anchors the cgm-nondiabetic-metabolic-wearables Signal to an exact source URL, study design, population, and endpoint.
Viral Vitalism Verdict
Useful evidence when kept inside its population, endpoint, and design limits.
Sources
- FDA clears first over-the-counter continuous glucose monitor - U.S. Food and Drug Administration
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
CGMs for Non-Diabetics: Metabolic Radar or Anxiety Subscription?
Continuous glucose monitors are moving from diabetes care into consumer metabolic self-tracking. That can help some people understand meals, sleep, stress, exercise, and risk. It can also turn normal physiology into false precision, food fear, and subscription anxiety.
VV Signal Score
58
Early or context-dependent
- Sources
- 7
- Studies
- 6
- Claims
- 4
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
sleep: Sleep duration, sleep quality, and sleep regularity are distinct
Sleep duration, sleep quality, and sleep regularity are distinct dimensions of sleep health, and consumer claims should avoid treating hours slept as the whole sleep signal.
sleep: Longitudinal commercial wearable sleep data can reveal associations between
Longitudinal commercial wearable sleep data can reveal associations between sleep duration, irregularity, sleep stages, and chronic disease incidence, but wearable sleep scores should not be treated as clinical-grade diagnosis.